Improving Treatment of Early Breast Cancer
- 5 Downloads
The January 2006 announcement that Medicare in California would reimburse the Oncotype DX™ gene-expression test for predicting clinical outcome and response to adjuvant therapy in patients with early breast cancer has focused attention on molecular prognostics for this disease. The fundamental drivers for development of this novel technology class are the size of the patient population, and the limitations of current clinical tools for predicting patient outcome and the risk/benefit of adjuvant treatment.
Only two molecular prognostic tests are currently marketed, Oncotype DX™ from Genomic Health and MammaPrint® from the Dutch company Agendia, both of which became commercially available only within the last 2 years. However, experimental gene-expression tests are undergoing clinical evaluation and research with Veridex, Ipsogen and the Centre for Genetic Engineering and Biotechnology in Cuba. Although this subclass of molecular diagnostics is still at early stages of...
KeywordsBreast Cancer Tamoxifen Early Breast Cancer Recurrence Score Molecular Diagnostics
- 1.American Cancer Society. Cancer facts and figures 2006. Atlanta (GA): American Cancer Society, 2006Google Scholar
- 6.Foekens AJ, Atkins D, Zhang, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. Epub 2006 Feb 27Google Scholar